Moderna's phase 3 cancer vaccine cuts tumor recurrence by 42%
mariolefebvre · x · 2026-10-25
Per InsiderWN breaking news: the world's first cancer vaccine cut tumor recurrence by 42% in Moderna's phase 3 trial — a major milestone for the personalized oncology vaccine pipeline.
More from Research
- arXiv paper: test collections may need expiration dates as neural rankers near human-level — bclavie · 2026-10-25
- FlashMap: flow map-based speculative decoding speeds up Qwen3-8B inference over 6x — caglarml · 2026-10-25
- CS papers near 18,000/month, up 10x since 2016, led by complexity and algorithms — burny_tech · 2026-10-25
- ICML Paper: Empowerment-Based Representations Are 1000x More Sensitive to Control-Relevant Features — burny_tech · 2026-10-25
- ETH Zurich teaches G1 robot to climb ladders with just 10 minutes of human data — Distinct-Question-16 · 2026-10-25
- New soft actuator weighs 15g, lifts 400g, costs under $3 to build — IanPritchard · 2026-10-25